Literature DB >> 26979639

Comparison of long-term oncological outcomes of appendiceal cancer and colon cancer: A multicenter retrospective study.

Il Tae Son1, Soyeon Ahn2, Kyu Joo Park3, Jae Hwan Oh4, Seung-Yong Jeong3, Hyoung-Chul Park5, Seung Chul Heo6, Eui Gon Youk7, Jin-Taek Park1, Myong Hoon Ihn1, Heung-Kwon Oh1, Duck-Woo Kim1, Kyoung Ho Lee8, Sung-Bum Kang9.   

Abstract

BACKGROUND: There has been no comparative study of the long-term oncological outcomes of appendiceal cancer and colon cancer. We hypothesized that the oncological outcome is worse in appendiceal cancer because perforation is more frequent than in colon cancer.
METHODS: Patients with stage I-III were selected from 5046 patients with appendiceal or colon cancer, between September 2001 and June 2010. The 5-year disease-free survival (DFS) was the primary endpoint. Multivariate analyses with Cox proportional hazards model for DFS and logistic regression model for perforation were conducted. A matching model was used to compensate for the heterogeneity between groups.
RESULTS: The perforation rate was 44.7% in appendiceal cancer (n = 47), but 1.1% in colon cancer (n = 2828) (p = 0.001). The 5-year DFS rate was lower in appendiceal cancer than in colon cancer (57.9% vs. 85.2%, p = 0.001; matching model, 54.2% vs. 78.4%, p = 0.038), with a higher rate of peritoneal seeding (25.5% vs. 2.5%, p = 0.001; matching model, 24.0% vs. 4.0%, p = 0.007). Multivariate Cox regression showed that appendiceal cancer was an independent prognostic factor for poor DFS (hazard ratio = 2.602, 95% confidence interval = 1.26-5.35, p = 0.009), and logistic regression confirmed that appendiceal cancer was the risk factor associated with perforation (odds ratio = 66.265, 95% confidence interval = 28.21-155.61, p = 0.001).
CONCLUSIONS: This study suggested that the long-term oncological outcomes are worse for appendiceal cancer than for colon cancer, attributed to higher perforation rate in appendiceal cancer.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Appendiceal cancer; Colon cancer; Disease-free survival

Mesh:

Year:  2015        PMID: 26979639     DOI: 10.1016/j.suronc.2015.12.006

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  4 in total

1.  Evaluation of repeat cytoreductive surgery and heated intraperitoneal chemotherapy for patients with recurrent peritoneal carcinomatosis from appendiceal and colorectal cancers: a multicentre Canadian study

Authors:  Evan Jost; Lloyd A. Mack; Lucas Sideris; Pierre Dube; Walley Temple; Antoine Bouchard-Fortier
Journal:  Can J Surg       Date:  2020-02-21       Impact factor: 2.089

2.  Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study.

Authors:  Ella Benzaquen; Yifan Wang; Stephanie Wiseman; Velka Rosenfeld; Lucas Sideris; Pierre Dubé; Jean-Sebastien Pelletier; Tsafrir Vanounou
Journal:  Can J Surg       Date:  2021-03-02       Impact factor: 2.089

3.  The association between appendicitis severity and patient age with appendiceal neoplasm histology-a population-based study.

Authors:  Jenny Alajääski; Elina Lietzén; Juha M Grönroos; Jukka-Pekka Mecklin; Ari Leppäniemi; Pia Nordström; Tero Rautio; Tuomo Rantanen; Juhani Sand; Hannu Paajanen; Helena Ollila; Paulina Salminen
Journal:  Int J Colorectal Dis       Date:  2022-04-26       Impact factor: 2.796

4.  A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC.

Authors:  Rachel M Lee; Adriana C Gamboa; Michael K Turgeon; Mohammad Y Zaidi; Charles Kimbrough; Jennifer Leiting; Travis Grotz; Andrew J Lee; Keith Fournier; Benjamin Powers; Sean Dineen; Joel M Baumgartner; Jula Veerapong; Harveshp Mogal; Callisia Clarke; Gregory Wilson; Sameer Patel; Ryan Hendrix; Laura Lambert; Courtney Pokrzywa; Daniel E Abbott; Christopher J LaRocca; Mustafa Raoof; Jonathan Greer; Fabian M Johnston; Charles A Staley; Jordan M Cloyd; Shishir K Maithel; Maria C Russell
Journal:  J Surg Oncol       Date:  2020-10-01       Impact factor: 3.454

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.